68426-83-5

Usage

Uses

Used in Pharmaceutical Industry:
5-Methoxy-1-methyl-1H-benzimidazole-2-methanol is used as an anthelmintic drug for the treatment of various helminth infections such as roundworm, whipworm, hookworm, and pinworm. It is effective in immobilizing and killing the parasites by inhibiting the formation of microtubules in their cells.
5-Methoxy-1-methyl-1H-benzimidazole-2-methanol is available in different forms, including tablets, chewable tablets, and oral suspensions, and is usually taken as a single dose or in a series of doses over a few days. However, it may cause side effects such as abdominal pain, diarrhea, and nausea in some individuals. Therefore, it is important for patients to follow their healthcare provider's instructions and dosage recommendations when taking this medication.

InChI:InChI=1/C10H12N2O2/c1-12-9-4-3-7(14-2)5-8(9)11-10(12)6-13/h3-5,13H,6H2,1-2H3

Upstream product

• 3360-79-0 N-methyl-4-methoxy-2-nitroaniline 
• 96-96-8 4-methoxy-2-nitroaniline 
• 20033-99-2 (5-methoxy-1H-benzimidazole-2-yl)-methanol 
• 74-88-4 methyl iodide 
• 102-51-2 4-methoxy-1,2-phenylenediamine 
• 79-14-1 glycolic Acid 
• 3360-78-9 4-methoxy-N-methyl-1,2-phenylenediamine 
• 10394-39-5 5-methoxy-1-methyl-1H-benzo[d]imidazole 

Downstream Products

• 1357162-29-8 C₂₁H₂₀N₂O₄ 
• 1357162-32-3 C₂₀H₁₈N₂O₄ 
• 1357162-38-9 C₂₁H₂₀N₂O₄ 
• 1357162-41-4 C₂₀H₁₈N₂O₄ 
• 53004-19-6 5-methoxy-1-methyl-1H-1,3-benzodiazole-2-carbaldehyde 

Relevant academic research and scientific papers

Lysophosphatidic acid receptor antagonists and preparation method thereof

The invention belongs to the technical field of medicinal chemistry, and particularly relates to lysophosphatidic acid receptor antagonists and a preparation method thereof. The applicant surprisinglyfinds that compounds provided by the invention have high LPAR1 antagonistic activity and selectivity, low toxicity, good metabolic stability and good drug development prospect, and can be used for preventing or treating diseases or symptoms related to LPAR1. The applicant also accidentally finds that the IC50 value of part of the compounds can be as low as 300 nM or below and even 50 nM or below.Moreover, the compounds disclosed by the invention have better safety, and the CC50 range of the compounds can reach 200 [mu]M or above. In addition, the compounds of the present invention have goodmetabolic stability in humans, rats, and mice, such excellent inhibitory activity being very desirable for their use as LPAR1 inhibitors in the above diseases or disorders. In addition, the preparation method of the compounds is simple, mild in reaction condition, high in product yield and suitable for industrial production.

Synthesis and evaluation of selected benzimidazole derivatives as potential antimicrobial agents

A library of 53 benzimidazole derivatives, with substituents at positions 1, 2 and 5, were synthesized and screened against a series of reference strains of bacteria and fungi of medical relevance. The SAR analyses of the most promising results showed that the antimicrobial activity of the compounds depended on the substituents attached to the bicyclic heterocycle. In particular, some compounds displayed antibacterial activity against two methicillin-resistant Staphylococcus aureus (MRSA) strains with minimum inhibitory concentrations (MICs) comparable to the widely-used drug ciprofloxacin. The compounds have some common features; three possess 5-halo substituents; two are derivatives of (S)-2-ethanaminebenzimidazole; and the others are derivatives of one 2-(chloromethyl)-1Hbenzo[ d]imidazole and (1H-benzo[d]imidazol-2-yl)methanethiol. The results from the antifungal screening were also very interesting: 23 compounds exhibited potent fungicidal activity against the selected fungal strains. They displayed equivalent or greater potency in their MIC values than amphotericin B. The 5-halobenzimidazole derivatives could be considered promising broad-spectrum antimicrobial candidates that deserve further study for potential therapeutic applications.

Synthesis of substituted benzimidazolyl curcumin mimics and their anticancer activity

A novel curcumin mimic library (14a-14h and 15a-15h) possessing variously substituted benzimidazole groups was synthesized through the aldol reaction of (E)-4-(4-hydroxy-3-methoxyphenyl)but-3-en-2-one (7) or (E)-4-(3-hydroxy-4- methoxyphenyl)but-3-en-2-one (13) with diversely substituted benzimidazolyl-2-carbaldehyde (12a-12h). The MTT assay of the cancer cells MCF-7, SH-SY5Y, HEP-G2, and H460 showed that compound 14c with IC50 of 1.0 and 1.9 μM has a strong inhibitory effect on the growth of SH-SY5Y and Hep-G2 cells, respectively, and that compound 15h with IC50 of 1.9 μM has a strong inhibitory effect on the growth of MCF-7 cancer cells.

Benzimidazole- and benzothiazole-quinones: Excellent substrates for NAD(P)H:quinone oxidoreductase 1

A series of benzimidazole- and benzothiazole-quinones has been synthesized. The ability of these heterocyclic quinones to act as substrates for recombinant human NAD(P)H:quinone oxidoreductase (NQO1), a two-electron reductase upregulated in tumour cells,

FREE-RADICAL HYDROXYMETHYLATION OF BENZIMIDAZOLE

Several benzimidazole derivatives were subjected to free-radical hydroxymethylation.Benzimidazole displays lower activity than quinoline in the first stage of the transformation, viz., in the addition of the hydroxymethyl radical.The yields of hydroxymeth